Luye Pharma Group (HKSE:02186) Gross-Profit-to-Asset % : 17.46% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Luye Pharma Group's annualized Gross Profit for the quarter that ended in Dec. 2023 was HK$4,946 Mil. Luye Pharma Group's average Total Assets over the quarter that ended in Dec. 2023 was HK$28,324 Mil. Therefore, Luye Pharma Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 17.46%.

Luye Pharma Group Gross-Profit-to-Asset % Historical Data

The historical data trend for Luye Pharma Group's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Gross-Profit-to-Asset % Chart

Luye Pharma Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

26.15

20.54

15.96

16.90

16.73

Luye Pharma Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															13.08	17.77	17.44	15.22	17.46

Competitive Comparison of Luye Pharma Group's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Luye Pharma Group's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's Gross-Profit-to-Asset % falls into.

Luye Pharma Group Gross-Profit-to-Asset % Calculation

Luye Pharma Group's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	4598.438	/	( (27079.913	+	27881.206)	/ 2 )
	=	4598.438	/	27480.5595
	=	16.73 %

Luye Pharma Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	4945.656	/	( (28766.638	+	27881.206)	/ 2 )
	=	4945.656	/	28323.922
	=	17.46 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Luye Pharma Group Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Luye Pharma Group (HKSE:02186) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (HKSE:02186) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

LYPHF:USA LUP:Germany LUP:Germany

Address

No. 15 Chuang Ye Road, High-tech Industrial Development Zone, Shandong, Yantai, CHN, 264003

Website

https://www.luye.cn

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Liu Dianbo	2301 Trustee
Luye Life Sciences Group Ltd	2201 Interest of corporation controlled by you
Luye Pharma Holdings Ltd.	2201 Interest of corporation controlled by you
Nelumbo Investments Limited	2201 Interest of corporation controlled by you
Shorea Lbg	2201 Interest of corporation controlled by you
Luye Pharmaceutical Investment Co., Ltd.	2101 Beneficial owner
Ginkgo (ptc) Limited	2301 Trustee
Luye Pharmaceutical International Co., Ltd.	2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Hillhouse Nev Holdings Limited	2101 Beneficial owner
Hillhouse Investment Management, Ltd.	2102 Investment manager
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Xin Ye Sheng Wu Yi Yao Kong Gu You Xian Gong Si
Yang Yu Fen

Luye Pharma Group (HKSE:02186) Headlines

No Headlines